Article Details

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of “Moderate Buy ...

Retrieved on: 2025-02-21 07:31:10

Tags for this article:

Click the tags to see associated articles and topics

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of “Moderate Buy .... View article details on hiswai:

Excerpt

Man Group plc bought a new position in Iovance Biotherapeutics in the 4th quarter valued at approximately $17,871,000. Assenagon Asset Management ...

Article found on: www.defenseworld.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo